Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

 Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

Shots:

  • Pieris to receive $10M upfront and is eligible to receive $353M in development, regulatory, and commercial based milestones along with royalties on sales of PRS-342. Pieris will also contribute an undisclosed amount for manufacturing activities
  • Boston to get exclusive worldwide rights to develop PRS-342 and will be primarily responsible for the development of the program, with both parties collaborating during the IND-enabling stage
  • PRS-342 is a 4-1BB/GPC3 preclinical immuno-oncology Anticalin-Ab bispecific fusion protein

Click here to­ read full press release/ article | Ref: Business Wire | Image: Mass Device

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post